Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Liabilities and Shareholders Equity (2016 - 2025)

Immucell (ICCC) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $45.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 2.88% year-over-year to $45.7 million, compared with a TTM value of $183.2 million through Sep 2025, up 5.78%, and an annual FY2024 reading of $45.1 million, up 2.95% over the prior year.
  • Liabilities and Shareholders Equity was $45.7 million for Q3 2025 at Immucell, down from $46.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $46.7 million in Q2 2025 and bottomed at $39.6 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $44.4 million, with a median of $44.5 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity increased 17.86% in 2022, then decreased 7.66% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $44.5 million in 2021, then grew by 0.89% to $44.9 million in 2022, then decreased by 2.35% to $43.8 million in 2023, then grew by 2.95% to $45.1 million in 2024, then rose by 1.4% to $45.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ICCC at $45.7 million in Q3 2025, $46.7 million in Q2 2025, and $45.6 million in Q1 2025.